Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Nature Structural & Molecular Biology|January 18, 2006
Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNAHeather C Losey, Alexander J Ruthenburg, Gregory L VerdineThe Journal of Pharmacology and Experimental Therapeutics|August 7, 2021
Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus MonkeysJared E Lopes, Lei Sun, Heather L Flick, et al.Biochemistry|May 5, 2004
Crystal structure of vancosaminyltransferase GtfD from the vancomycin biosynthetic pathway: interactions with acceptor and nucleotide ligandsAnne M Mulichak, Wei Lu, Heather C Losey, et al.Proceedings of the National Academy of Sciences of the United States of America|July 23, 2003
Structure of the TDP-epi-vancosaminyltransferase GtfA from the chloroeremomycin biosynthetic pathwayAnne M Mulichak, Heather C Losey, Wei Lu, et al.Acta Crystallographica. Section D, Biological Crystallography|June 22, 2002
Purification, crystallization and preliminary structural studies of dTDP-4-keto-6-deoxy-glucose-5-epimerase (EvaD) from Amycolatopsis orientalis, the fourth enzyme in the dTDP-L-epivancosamine biosynthetic pathwayAlexandra B Merkel, Genevieve K Temple, Michael D Burkart, et al.Journal for Immunotherapy of Cancer|April 23, 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJared E Lopes, Jan L Fisher, Heather L Flick, et al.Journal of the American Chemical Society|August 1, 2002
The structural basis for induction of VanB resistanceSteven D Dong, Markus Oberthür, Heather C Losey, et al.Chemistry & Biology|December 25, 2002
Incorporation of glucose analogs by GtfE and GtfD from the vancomycin biosynthetic pathway to generate variant glycopeptidesHeather C Losey, Jiqing Jiang, John B Biggins, et al.Journal for Immunotherapy of Cancer|April 11, 2024
Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeuticsYee Peng Phoon, Jared E Lopes, Lukas W Pfannenstiel, et al.Journal for Immunotherapy of Cancer|December 6, 2022
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancerYuanwang Pan, Yuan Hao, Han Han, et al.Pageof 1